
Replimune Group, Inc. (NASDAQ:REPL) stock plunged on Tuesday after a U.S. Food and Drug Administration (FDA) update.
The clinical stage biotechnology company received an FDA Complete Response Letter (CRL) regarding the Biologics License Application (BLA) for RP1 (vusolimogene oderparepvec) in combination with Bristol-Myers Squibb Co.’s (NYSE:BMY) Opdivo (nivolumab) for advanced melanoma.